Patents Assigned to Allergan, Inc.
  • Patent number: 10881608
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 5, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Patent number: 10874722
    Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: December 29, 2020
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld
  • Patent number: 10874605
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 29, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Thierry Nivaggioli, James Jane-Guo Shiah, Qing Lin
  • Patent number: 10869955
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Patent number: 10864661
    Abstract: Devices and methods are provided for making a variable textured breast implant when used in conjunction with a breast implant mandrel having a molding surface and a stem depending therefrom.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 15, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Robert L. Nieto, Claudia Renteria, Phat Ngo, David Schuessler, Dennis Van Epps
  • Patent number: 10864218
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: December 15, 2020
    Assignee: ALLERGAN, INC.
    Inventor: Patrick M. Hughes
  • Patent number: 10842739
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 24, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 10806628
    Abstract: A container-closure system includes a container configured to hold a therapeutic liquid and having a dispensing tip configured to dispense a dose of the therapeutic liquid. A vented cap is configured to fit over at least a portion of the container including the dispensing tip and having one or more vents that allow air to pass into and out of a cavity defined between the vented cap and the dispensing tip. A second cap is configured to fit over at least a portion of the vented cap. A tamper evident seal is coupled to the second cap and one or both of the container and the vented cap.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: October 20, 2020
    Assignee: ALLERGAN, INC.
    Inventor: Sai Shankar
  • Patent number: 10799518
    Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: October 13, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
  • Patent number: 10800744
    Abstract: The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 13, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Patent number: 10792288
    Abstract: The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: October 6, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
  • Patent number: 10792345
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 6, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 10792427
    Abstract: Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. The assisted syringes can be used to inject or extrude viscous materials.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 6, 2020
    Assignee: Allergan, Inc.
    Inventors: Jason S. Metzner, Zachary Dominguez, Justin J. Schwab, Ethan Franklin, Mike Augarten
  • Patent number: 10780218
    Abstract: Apparatus and methods for introducing a solid or semi-solid intraocular drug-containing implant into the anterior chamber of an eye are described. The drug-containing implant can be a rod-shaped biodegradable implant that may provide for the extended release of the drug and may be effective for treating a medical condition of the eye. The apparatus is ergonomically designed in the shape or style of a pen with tactile surfaces for easy gripping, a needle-rotation knob to permit orientation of the needle bevel in relation to the eye, and a spring-actuated mechanism for consistent deployment of the implant.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: September 22, 2020
    Assignee: Allergan, Inc.
    Inventors: Zoran Novakovic, Rahul Bhagat, Shawn R. Davis, David Mucientes, Michael R. Robinson, Vaclav Vojan, Michael Strehl, Ina Michaelis, Maximilian Vogl, Jessica Kreher
  • Patent number: 10780098
    Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: September 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
  • Patent number: 10780048
    Abstract: The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: September 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Hao Hou, Chetan P. Pujara, Sesha Neervannan, Ke Wu
  • Patent number: 10765629
    Abstract: Described herein is a solid complex comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter “Compound 1”) and ?-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: September 8, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ke Wu, Evgenyi Shalaev, Prem Swaroop Mohanty, Jinping Wan
  • Patent number: 10765506
    Abstract: A laminate useful as a component of a medical implant, for example, useful as a component of an inflatable tissue expander. The laminate includes a base layer, an intermediate layer, and a top layer. When used as a component of a tissue expander, the laminate enables an internal chamber pressure of about 2.5 psi with an expander exterior compressive force of about 40 lbs.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: September 8, 2020
    Assignee: Allergan, Inc.
    Inventors: Kaustubh S. Chitre, Nicholas Manesis, Nikhil S. Trilokekar, Dustin Leslie, David J. Schuessler
  • Patent number: 10765501
    Abstract: A soft breast prosthesis is provided, the prosthesis having a surface configuration advantageous for dual plane placement of the prosthesis in a breast.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: September 8, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Dennis E. Van Epps, David J. Schuessler
  • Patent number: D896383
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: September 15, 2020
    Assignee: Allergan, Inc.
    Inventors: David J. Schuessler, Alberto J. Flores, Daniela Rodriguez, Luis M. Solano